Integrin-Targeted Liposomes for Immune Cell Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating pathologies, such as atherosclerotic plaques and tumors, lack effective targeting mechanisms for activated immune cells, limiting the sensitivity and specificity of imaging and therapeutic interventions.
Innovation Solution
Development of integrin targeting agents, specifically compounds and liposomes with integrin-targeting moieties, that selectively bind to α4β1 integrin-expressing cells, enabling enhanced imaging and drug delivery by forming liposomes with contrast agents for MRI imaging at clinically relevant field strengths.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used for monitoring immune cells in pathologies, then the imaging can be performed with existing technology, but the sensitivity and specificity of detecting activated immune cells is insufficient
Solution Approach 1:
The patent applies local quality by functionalizing the nanoparticle surface with specific ligands (such as RGD peptides, antibodies, or aptamers) that selectively bind to integrin receptors overexpressed on activated immune cells. This localized molecular recognition capability enables the imaging agent to specifically target and accumulate at sites of inflammation or tumor infiltration, thereby enhancing both the sensitivity and specificity of immune cell detection compared to conventional non-specific imaging methods.
2Measurement precision
If targeting ligands are coupled to nanoparticles, then specificity to activated immune cells is improved, but the complexity of nanoparticle fabrication increases
Solution Approach 1:
The patent employs preliminary action by pre-synthesizing and purifying the targeting ligands (such as RGD peptides, antibodies, or aptamers) before coupling them to the nanoparticle surface. The ligands are prepared in advance with appropriate functional groups (e.g., carboxyl, amine, or thiol groups) that facilitate controlled attachment to the nanoparticle. This pre-preparation approach simplifies the overall fabrication process by separating the ligand synthesis and characterization steps from the nanoparticle assembly, thereby reducing fabrication complexity while maintaining high targeting specificity.
3Productivity
If nanoparticles are used for drug delivery to immune cells, then therapeutic delivery is enhanced, but the challenge of delivering through biological barriers remains
Solution Approach 1:
The patent utilizes composite materials by constructing multifunctional nanoparticles that integrate therapeutic agents (such as chemotherapeutic drugs, siRNA, or proteins) with targeting ligands and imaging contrast agents in a single nanoscale platform. The nanoparticle core provides drug loading capacity, the surface is functionalized with integrin-specific ligands for targeted delivery, and contrast agents (such as superparamagnetic iron oxide or gold nanoparticles) are incorporated for real-time tracking. This composite structure enables simultaneous targeted drug delivery and imaging, enhancing therapeutic delivery efficiency while allowing monitoring of delivery reliability through imaging modalities.
Data Source
Figure 1
Figure 2~2C
Figure 3~3B
AI summary
Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.